Clinical trial
Glycine vs Placebo for the Schizophrenia Prodrome
NCT00291226 · Yale University, Other · Completed
Key facts
| NCT number | NCT00291226 |
|---|---|
| Title | Glycine vs Placebo for the Schizophrenia Prodrome |
| Official title | Glycine vs Placebo for the Schizophrenia Prodrome |
| Lead sponsor | Yale University, Other |
| Collaborators | Glytech, Inc Industry National Alliance for Research on Schizophrenia and Depression |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia Prodrome |
| Intervention type | Drug |
| Interventions | Glycine, Placebo |
| Enrollment | 8 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Feb 13, 2006 |
| Last update posted | Apr 2, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: